
Global R&D Pipeline
My Favorite
Hot Targets:
TSLP
Back
Total number of drugs
73
Phase II and later clinical stages
19.2%
Involving companies
90
Main therapeutic areas
Immune System Diseases
Data Table
Data Chart
Select Row
Fixed Column
Download Table
Molecule Info
R&D and Market Info
ADC Info
| Drug | Drug Name En | Drug Type | Treatment Field | Mechanism of Action | Originator | Developer | Indication | Highest Development Stage | Highest Development Stage (China) | Approved Countries/Regions | Approved Time | Approved Time (China) | Special Review | ADC Type | ADC Linker | ADC Payload | ADC DAR | Drug Name | Antibody Type | ADC Linking Site | Operation |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| US20240254108 | US20240254108 | Small molecule drug | Respiratory Diseases Skin and Musculoskeletal Diseases | - | Beadtech, Inc. Co. Ltd. | Beadtech, Inc. Co. Ltd. | Discovery | - | - | - | - | - | - | - | - | - | US20240254108 | - | - | detail > | |
| HXN-1011 | HXN-1011 | Bispecific antibody | Immune System Diseases Respiratory Diseases | TSLP inhibitors | Helixon US, Inc. | Helixon US, Inc. | Preclinical | - | - | - | - | - | - | - | - | - | HXN-1011 | - | - | detail > | |
| TSLP x IL-13 (Generate) | TSLP x IL-13 (Generate) | Bispecific antibody | Immune System Diseases Congenital Disorders Skin and Musculoskeletal Diseases | IL-13 inhibitors TSLP inhibitors | Generate Biomedicines, Inc. | Generate Biomedicines, Inc. | Preclinical | - | - | - | - | - | - | - | - | - | TSLP x IL-13 (Generate) | - | - | detail > | |
| APG333/APG-777 | APG333/APG-777 | Monoclonal antibody | Immune System Diseases Respiratory Diseases | IL-13 inhibitors TSLP inhibitors | Paragon Therapeutics, Inc. | Paragon Therapeutics, Inc.Apogee Therapeutics, Inc. | Preclinical | - | - | - | - | - | - | - | - | - | APG333/APG-777 | - | - | detail > | |
| WO2024186635 | WO2024186635 | Bispecific antibody | Neoplasms Immune System Diseases Nervous System Diseases Cardiovascular Diseases Digestive System Disorders Endocrinology and Metabolic Disease Respiratory Diseases Skin and Musculoskeletal Diseases Urogenital Diseases Other Diseases | - | Celldex Therapeutics, Inc. | Celldex Therapeutics, Inc. | Discovery | - | - | - | - | - | - | - | - | - | WO2024186635 | - | - | detail > | |
| WO2023116925 | WO2023116925 | Antibody | Neoplasms Immune System Diseases Cardiovascular Diseases Congenital Disorders Digestive System Disorders Eye Diseases Respiratory Diseases Skin and Musculoskeletal Diseases Urogenital Diseases Other Diseases | - | Inmagene Biopharmaceuticals (Hangzhou) Co., Ltd. | Inmagene Biopharmaceuticals (Hangzhou) Co., Ltd. | Discovery | - | - | - | - | - | - | - | - | - | WO2023116925 | - | - | detail > | |
| TSLP/IL-33 Bispecific Antagonist (Odyssey) | TSLP/IL-33 Bispecific Antagonist (Odyssey) | Fusion protein | Immune System Diseases Respiratory Diseases | IL-33 inhibitors TSLP inhibitors | Odyssey Therapeutics, Inc. | Odyssey Therapeutics, Inc. | Discovery | - | - | - | - | - | - | - | - | - | TSLP/IL-33 Bispecific Antagonist (Odyssey) | - | - | detail > | |
| WO2022253147 | WO2022253147 | Monoclonal antibody | Neoplasms Immune System Diseases Digestive System Disorders Respiratory Diseases Skin and Musculoskeletal Diseases Urogenital Diseases Other Diseases | - | QureBio Ltd. | QureBio Ltd. | Discovery | - | - | - | - | - | - | - | - | - | WO2022253147 | - | - | detail > | |
| TSLP(Scinai) | TSLP(Scinai) | Monoclonal antibody | Immune System Diseases Congenital Disorders Respiratory Diseases Skin and Musculoskeletal Diseases | TSLP inhibitors | Scinai Immunotherapeutics Ltd. | Scinai Immunotherapeutics Ltd.University Medical Center GöttingenThe Max Planck Institute | Preclinical | - | - | - | - | - | - | - | - | - | TSLP(Scinai) | - | - | detail > | |
| CN117327176 | CN117327176 | Monoclonal antibody | Immune System Diseases Respiratory Diseases | - | RegeneCore Biotech Co., Ltd | RegeneCore Biotech Co., Ltd | Discovery | - | - | - | - | - | - | - | - | - | CN117327176 | - | - | detail > |
Total 73 data
1
2
3
4
5
6
7
8


